Drug evaluation: Bay-59-8862.

Abstract	Bayer Corp, under license from Indena SpA, is developing BAY-59-8862, a taxane synthesized from 14beta-hydroxy-10-deacetylbaccatin III, for the potential treatment of cancer.
Authors	Jens W Eckstein
Journal	IDrugs : the investigational drugs journal (IDrugs) Vol. 7 Issue 6 Pg. 575-81 (Jun 2004) ISSN: 1369-7056 [Print] England
PMID	15197663 (Publication Type: Journal Article, Review)
Chemical References	Antineoplastic Agents Bridged-Ring Compounds Taxoids IDN 5109
Topics	Animals Antineoplastic Agents (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use, toxicity) Breast Neoplasms (drug therapy) Bridged-Ring Compounds (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use, toxicity) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Drug Evaluation, Preclinical Female Humans Ovarian Neoplasms (drug therapy) Structure-Activity Relationship Taxoids (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!